News und Analysen
Illumina Reports Financial Results for First Quarter of Fiscal Year 2021
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2021.
First quarter results reflect record revenue:
-
Revenue of $1,093 million, a 27%
Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s
Agilent LC/MS Instruments Receive ACT Labels from My Green Lab
Agilent Technologies Inc. (NYSE: A) announced today that both the InfinityLab LC/MSD iQ and the Ultivo Triple Quadrupole LC/MS systems have earned the highly-respected Accountability, Consistency
Pfizer Declares Second-Quarter 2021 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent second-quarter 2021 dividend on the company’s common stock, payable June 4, 2021, to holders of the Common
Agilent Named One of the Best U.S. Companies for Diversity for Third Straight Year
Agilent Technologies (NYSE: A) today was named one of the top U.S. companies for diversity, marking the third straight year it has been recognized for its commitment to fostering a diverse and
Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with the European Commission’s Directorate-General for Competition’s decision to review Illumina’s acquisition of GRAIL, a company
Agilent Completes Acquisition of Resolution Bioscience, Expands Role in Fast-growing NGS Market for Precision Oncology
Agilent Technologies, Inc. (NYSE: A) today announced it has completed the acquisition of Resolution Bioscience, a leader in the development and commercialization of next-generation sequencing
Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22
Pfizer Inc. (NYSE: PFE) announced today that shareholders and the general public are invited to access its virtual-only 2021 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 22
Agilent Named One of Singapore’s Best Employers
Agilent Technologies Inc. (NYSE: A) today announced that Agilent Singapore has been recognized as one of Singapore’s Best Employers in 2021 for the second year-in-a-row by The Straits Times, a
Waters and Genovis Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization
Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has extended the priority review period for the New Drug Application (NDA) for abrocitinib for the treatment
Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance. Subject to quarter-end closing
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021
Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of a presentation and conference call with investment analysts at 10 a.m. EDT on Friday, April 9
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the
Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with, and will oppose, the U.S. Federal Trade Commission (FTC)’s challenge to its previously announced acquisition of GRAIL, a
Humana Healthy Horizons Partners with GoNoodle® to Boost Physical and Mental Health for 2.4 Million Kids
Humana Healthy Horizons, the Medicaid business of leading health and well-being company Humana Inc. (NYSE: HUM), announced a partnership with GoNoodle®, an interactive mindfulness and physical
Agilent Awards Octagon Therapeutics with a Golden Ticket at LabCentral
Agilent Technologies Inc. (NYSE: A) announces that Octagon Therapeutics has been awarded an Agilent Golden Ticket at LabCentral. The Golden Ticket was presented to Octagon during a virtual online
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk
Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer
Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in combination with letrozole was
The Humana Foundation Awards Nearly $1 Million in a Second Year Investment to Kingsley House and Growing Local Food Collaborative
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, announces its second year of investments, totaling nearly $1 million in two local projects in the greater
Epic and Humana Deliver on Commitment to Enhance Connectivity and Collaboration Among Patients, Providers, and Health Plans
Humana Inc. (NYSE: HUM), a leading health and well-being company, and Epic, developer of the nation’s most widely used comprehensive health record, have completed the first stage of a joint effort
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) announced today that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the
Humana Adds H Mart to List of National Retailers for Healthy Foods Card Benefit
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies and H Mart, the largest Asian supermarket chain in the U.S., announced today a collaboration to combat food
Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2021. The purpose of